Stock GENNEX6 GENNEX LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gennex Laboratories Limited

Equities

GENNEX6

INE509C01026

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:25:44 31/05/2024 BST 		5-day change 1st Jan Change
17.16 INR +1.00% Intraday chart for Gennex Laboratories Limited -9.06% +2.08%
02-14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
02-14 Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director) CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 470.6 393.4 235.3 494.6 952.6 1,004
Enterprise Value (EV) 1 495.1 437.2 283 566.5 978.9 1,036
P/E ratio 56.4 x 17.7 x 12.7 x 12.3 x 24.3 x 16.7 x
Yield - - - - - -
Capitalization / Revenue 1.06 x 0.7 x 0.42 x 0.82 x 1.56 x 1.53 x
EV / Revenue 1.12 x 0.78 x 0.5 x 0.94 x 1.6 x 1.58 x
EV / EBITDA 16.3 x 9.22 x 7.23 x 8.03 x 17.9 x 20.8 x
EV / FCF 24.7 x -19.4 x -38.4 x -20.6 x 32.8 x -5.89 x
FCF Yield 4.05% -5.15% -2.61% -4.86% 3.05% -17%
Price to Book 1.48 x 1.16 x 0.66 x 1.25 x 2.17 x 1.23 x
Nbr of stocks (in thousands) 126,503 126,503 126,503 126,503 126,503 179,010
Reference price 2 3.720 3.110 1.860 3.910 7.530 5.610
Announcement Date 06/07/18 06/09/19 06/09/20 08/09/21 09/09/22 09/09/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 443.4 563.4 562.3 600.4 612.1 656
EBITDA 1 30.45 47.44 39.12 70.53 54.76 49.7
EBIT 1 21.23 37.59 29.07 61.72 46.88 40.51
Operating Margin 4.79% 6.67% 5.17% 10.28% 7.66% 6.17%
Earnings before Tax (EBT) 1 14.53 30.27 25.49 50.62 50.94 63.73
Net income 1 8.358 22.21 18.56 40.38 39.23 49.21
Net margin 1.88% 3.94% 3.3% 6.73% 6.41% 7.5%
EPS 2 0.0660 0.1755 0.1467 0.3190 0.3101 0.3369
Free Cash Flow 1 20.03 -22.5 -7.372 -27.55 29.87 -175.8
FCF margin 4.52% -3.99% -1.31% -4.59% 4.88% -26.8%
FCF Conversion (EBITDA) 65.78% - - - 54.54% -
FCF Conversion (Net income) 239.68% - - - 76.13% -
Dividend per Share - - - - - -
Announcement Date 06/07/18 06/09/19 06/09/20 08/09/21 09/09/22 09/09/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 24.5 43.8 47.7 71.8 26.3 31.3
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.8054 x 0.9234 x 1.219 x 1.018 x 0.4808 x 0.6294 x
Free Cash Flow 1 20 -22.5 -7.37 -27.5 29.9 -176
ROE (net income / shareholders' equity) 2.67% 6.77% 5.34% 10.7% 9.39% 7.55%
ROA (Net income/ Total Assets) 2.66% 4.6% 3.34% 6.66% 4.62% 2.53%
Assets 1 313.9 483 555.1 606.4 849.8 1,947
Book Value Per Share 2 2.510 2.670 2.820 3.140 3.460 4.550
Cash Flow per Share 2 0.0100 0.0200 0.0200 0.0200 0.5900 0.8000
Capex 1 7.62 10.4 2.95 0.79 3.9 398
Capex / Sales 1.72% 1.85% 0.52% 0.13% 0.64% 60.65%
Announcement Date 06/07/18 06/09/19 06/09/20 08/09/21 09/09/22 09/09/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
GENNEX LABORATORIES LIMITED Stock Gennex Laboratories Limited
+2.08% 46.77M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GENNEX6 Stock
  4. Financials Gennex Laboratories Limited